Johnson Investment Counsel Inc. Sells 1,415 Shares of Zoetis Inc. $ZTS

Johnson Investment Counsel Inc. lowered its stake in Zoetis Inc. (NYSE:ZTS) by 0.3% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 489,773 shares of the company’s stock after selling 1,415 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Zoetis were worth $76,380,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of ZTS. Nuveen LLC bought a new stake in shares of Zoetis in the 1st quarter valued at $616,375,000. Mackenzie Financial Corp increased its stake in Zoetis by 4,158.3% during the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock valued at $300,481,000 after purchasing an additional 1,782,110 shares in the last quarter. Polen Capital Management LLC increased its stake in Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares in the last quarter. Amundi increased its stake in Zoetis by 30.8% during the 1st quarter. Amundi now owns 3,595,628 shares of the company’s stock valued at $575,691,000 after purchasing an additional 846,909 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd increased its stake in Zoetis by 475.9% during the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock valued at $148,228,000 after purchasing an additional 743,926 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $141.05 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The company has a market capitalization of $62.51 billion, a price-to-earnings ratio of 24.28, a P/E/G ratio of 2.26 and a beta of 0.90. The firm’s fifty day moving average price is $149.24 and its two-hundred day moving average price is $154.41. Zoetis Inc. has a 1 year low of $139.34 and a 1 year high of $196.55.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is 34.42%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent research reports. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a report on Wednesday. Four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $196.71.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.